Business Wire

PPSS-GROUP

Share
PPSS Group Finds Incidents Of Health Care Worker Being Bitten Leads To Demand For Bite Resistant Clothing

According to BitePRO , the demand for bite resistant clothing is growing dramatically as an increasing numbers of human bite related incidents are being recorded and published.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190828005327/en/

PPSS Group , the UK firm behind BitePRO, has seen an increase of 241% in sales for this unique brand alone in the past 12 months.

The case of Australia based mental health care nurse Jessica Anderson, who was bitten by one of her patients in a psychiatric hospital in Melbourne made the headlines in 2017.

Many others have spoken up since, highlighting the immense physical pain and sometimes long-lasting psychological distress after being bitten by another human.

It is a well-known fact that working within the health care sector comes with a certain risk, according to Robert Kaiser, CEO of PPSS Group, but he is also stating: “These environments would unquestionably be much safer places to work if the appropriate protection was being offered.”

“BitePRO can absolutely be deemed as appropriate, especially in workplaces where the risk of biting, scratching, pinching is determined, either by behavioural tendencies or history and previous incidents.”

According to other resources, bite related injuries can become infected and contaminated with pathogens. Transmissions of potentially life-threatening viruses, such as Hepatitis B, Hepatitis C or HIV are also a possibility.

Robert Kaiser is commenting further, by saying: “Human bites can often lead to infection because of the amount of bacteria and viruses in a human mouth. If you have a bite that has become infected, you will require immediate medical attention.”

The American Journal of Forensic Medicine and Pathology states that bite injuries represent 1% of all emergency department admissions in the United States.

Data released by the UK’s NHS Security Management Service reveals that mental health care professionals are far more likely to be attacked than other health care workers and frontline professionals.

BitePRO is featuring a range of bite resistant clothing and arm guards, designed to protect public facing professionals working within mental health care, general health care or educational facilities dedicated to special educational needs.

All garments are made from the highly acclaimed Cut-Tex PRO fabric, preventing teeth from breaking the skin, effectively reducing the risks of serious injury and infection associated with human bites.

David Watts, Director of Risk and Safety of Priory Group, one of the UK’s leading and most respected provider of mental health care clinics stated: “Whilst we are in the fortunate position to only need to use BitePRO bite proof clothing and arm guards in very rare circumstances, when it has been used, we have received very favourable feedback. I am certain that the use of this equipment has helped to advert serious incidents and serious injury.”

In case you have any product or brand related questions, please visit www.bite-pro.com or email info@bite-pro.com .

END

About PPSS Group:

PPSS Group is specialised in the development, manufacturing and supply of high-performance personal protective equipment, offering unrivalled protection from edged weapons, blunt force trauma and even human bites. The BitePRO brand is part of PPSS Group’s global operation. Please follow BitePRO on social media: Facebook , LinkedIn , Twitter and Instagram .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 11:15:00 CEST | Press release

− Sustained Benefit of Vutrisiran Across Mortality, Cardiovascular Events, Quality of Life and Cardiac Biomarkers Observed Through Up to 48 Months, Including 12 Months from the Ongoing Open-Label Extension, Reinforce Potential as First-Line Treatment for ATTR-CM –− Vutrisiran, which Delivers Rapid Knockdown of Transthyretin, Reduced the Risk of Composite of All-Cause Mortality or First Cardiovascular Event by 37% in the Overall Population and 42% in the Monotherapy Group During the Same Period – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Card

WETEX Opens Broad Investment Horizons for International Companies31.8.2025 08:30:00 CEST | Press release

DEWA will organise the exhibition from 30 September to 2 October 2025 Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial i

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 18:00:00 CEST | Press release

Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management. Recent findings from MILOS and SANTORINI registries presented at ESC Congress 2025, highlight ongoing challenges in accurately assessing cardiovascular (CV) risk and helping patients reach LDL-C targets.1-5 Furthermore, data from a four-country cohort of the MILOS study support the real-world effectiveness and safety of bempedoic acid in both sexes.6 Simulation using SANTORINI data reveals the potential of improved LDL-C goal attainment with tailored oral combination therapy of statins, ezetimibe and bempedoic acid, in line with the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.7,8 Daiichi Sankyo has a long-standing commitment to easing treatment of cardiovascular disease (CVD) and exploring new treatment options that improve CVD outcomes and treatment adherence. Daiich

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 16:30:00 CEST | Press release

- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society of Cardiology Congress 2025 -- Zilebesiran Demonstrated Clinically Meaningful Reductions in Office Systolic Blood Pressure in Patients with Uncontrolled Hypertension and High Cardiovascular Risk at Month 3 Primary Endpoint, with Continuous Control Through Month 6 -- Zilebesiran Displayed Encouraging Safety When Combined with Two or More Antihypertensives -- Results Support Biannual Dosing Regimen and Inform Phase 3 Trial Design: Trial Expected to Initiate by Year-End 2025 -- Alnylam to Host Webcast Investor Event on August 30, 2025, at 1:00 pm ET (7:00 pm CEST) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from t

Andersen Consulting styrker sine kompetencer inden for virksomhedstransformation med Fabric29.8.2025 17:01:00 CEST | Pressemeddelelse

Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Fabric, der er et strategisk designfirma, der arbejder med organisationer for at integrere bæredygtighed, forsyningskæder og menneske-centreret innovation på tværs af kultur og drift. Fabric blev grundlagt i Japan i 2021 og arbejder sammen med virksomheder og globale brands om at skabe regenerative forretningsmodeller sammen samt bæredygtige brandstrategier og fremtidssikrede produkter. Ved hjælp af strategiske designmetoder og designfilosofi skaber virksomheden indsigtsbaseret transformation på tværs af forsyningskæder, brand og HR. Fabric er kendt for sin systemtænkning og sit engagement i social og miljømæssig bæredygtighed og fremmer desuden digitale transformationsinitiativer, der integrerer bæredygtighed, humankapital og AI. "Fabric er skabt for at hjælpe virksomheder med at blomstre gennem regenerative relationer til mennesker, samfund og forbundne, levende systemer," sagde James Hollow, der er grundlægger a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye